Literature DB >> 19604257

Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases.

C Hu1, F S Wong, L Wen.   

Abstract

B cells play an important role in the pathogenesis of both systemic and organ-specific autoimmune diseases. Autoreactive B cells not only produce autoantibodies, but are also specialized to present specific autoantigens efficiently to T cells. Furthermore, these B cells can secrete proinflammatory cytokines and can amplify the vicious cycle of self-destruction. Thus, B cell-directed therapies are potentially an important approach for treating autoimmune diseases. On the other hand, like T cells, there are subsets of B cells that produce anti-inflammatory cytokines and are immunosuppressive. These regulatory B cell subsets can protect against and ameliorate autoimmune diseases. Thus targeting B cells therapeutically will require this balance to be considered. Here we summarize the roles of pathogenic and regulatory B cells and current applications of B cell-directed therapy in autoimmune diseases. Considerations for future development of B cell-directed therapy for autoimmune diseases have also been discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19604257      PMCID: PMC2730843          DOI: 10.1111/j.1365-2249.2009.03977.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  106 in total

1.  Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice.

Authors:  J Tian; D Zekzer; L Hanssen; Y Lu; A Olcott; D L Kaufman
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

Review 2.  The role of platelet CD154 in the modulation in adaptive immunity.

Authors:  Daniel L Sprague; Jennifer M Sowa; Bennett D Elzey; Timothy L Ratliff
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

3.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

Review 4.  Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy.

Authors:  M J Leandro; I de la Torre
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

5.  Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmacytic lymphoma.

Authors:  Y Cohen; A Polliack; O Zelig; A Goldfarb
Journal:  Leuk Lymphoma       Date:  2001 Nov-Dec

6.  Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice.

Authors:  Siri Atma W Greeley; Makoto Katsumata; Liping Yu; George S Eisenbarth; Daniel J Moore; Heidi Goodarzi; Clyde F Barker; Ali Naji; Hooman Noorchashm
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

Review 7.  The 'short' history of regulatory B cells.

Authors:  Claudia Mauri; Michael R Ehrenstein
Journal:  Trends Immunol       Date:  2007-12-03       Impact factor: 16.687

Review 8.  BAFF and the regulation of B cell survival.

Authors:  Pascal Schneider; Jürg Tschopp
Journal:  Immunol Lett       Date:  2003-07-03       Impact factor: 3.685

Review 9.  Lymphoid neogenesis in chronic inflammatory diseases.

Authors:  Francesca Aloisi; Ricardo Pujol-Borrell
Journal:  Nat Rev Immunol       Date:  2006-03       Impact factor: 53.106

10.  Immunoregulatory role of CD40 in human B cell differentiation.

Authors:  J B Splawski; S M Fu; P E Lipsky
Journal:  J Immunol       Date:  1993-02-15       Impact factor: 5.422

View more
  5 in total

1.  B cell depletion therapy exacerbates murine primary biliary cirrhosis.

Authors:  Amy Dhirapong; Ana Lleo; Guo-Xiang Yang; Koichi Tsuneyama; Robert Dunn; Marilyn Kehry; Thomas A Packard; John C Cambier; Fu-Tong Liu; Keith Lindor; Ross L Coppel; Aftab A Ansari; M Eric Gershwin
Journal:  Hepatology       Date:  2010-12-28       Impact factor: 17.425

Review 2.  Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.

Authors:  Miglena G Prabagar; Hyeong-jwa Choi; Jin-Yeon Park; Sohee Loh; Young-Sun Kang
Journal:  Clin Exp Med       Date:  2013-09-01       Impact factor: 3.984

Review 3.  Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes.

Authors:  Bart O Roep; Mark Peakman
Journal:  Nat Rev Immunol       Date:  2010-02       Impact factor: 53.106

Review 4.  Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.

Authors:  M C Levesque
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 5.  Mechanisms by Which B Cells and Regulatory T Cells Influence Development of Murine Organ-Specific Autoimmune Diseases.

Authors:  Jason S Ellis; Helen Braley-Mullen
Journal:  J Clin Med       Date:  2017-01-26       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.